Gracell Biotechnologies Inc. (GRCL)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Gracell Biotechnologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 236,715 | $1.43M | $2.43M | $996,570.15 | 69.7% |
Gracell Biotechnologies Inc. (GRCL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gracell Biotechnologies Inc. ever had a stock split?
Gracell Biotechnologies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Wei Cao BM, CEO | NASDAQ (NGS) Exchange | 38406L103 CUSIP |
| CN Country | 314 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and advancement of cell-based therapies, particularly aimed at cancer treatment within the People's Republic of China. Since its establishment in 2017, the company has been at the forefront of innovation in the biopharmaceutical field, focusing on the development of advanced therapies that leverage the potential of CAR-T cell treatments. Gracell's headquarters are located in Suzhou, China, and the company is committed to improving patient outcomes through innovative therapeutic solutions that target various forms of cancer.
Products and Services
- GC012F: This is a FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19. Currently undergoing Phase I clinical trials, GC012F is aimed at treating multiple myeloma, showcasing the potential for targeted cell therapy in hematological malignancies.
- GC019F: An autologous CAR-T therapy enabled by FasTCAR, GC019F specifically targets CD19 and is advancing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL). Additionally, it is in preclinical development for treating relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL), highlighting the versatile applications of this therapy.
- GC027: This TruUCAR-powered allogeneic CAR-T product targets CD7 and is currently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. The innovative nature of GC027 aligns with Gracell's vision of expanding the potential of CAR-T therapies to multiple T-cell malignancies.
- GC007g: A donor-derived allogeneic CAR-T cell therapy that aims at CD19, GC007g is currently involved in a Phase 1/2 registrational study addressing r/r B-ALL. This product exemplifies the company's commitment to providing off-the-shelf treatment options for patients in need.
- GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, GC502 is in Phase I trials for various B-cell malignancies. This product underscores the company's focus on developing flexible and scalable therapeutic options for clinicians and patients alike.
In addition to these leading products, Gracell Biotechnologies maintains a broader pipeline of earlier-stage therapeutic candidates that target various oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. This expansive portfolio emphasizes Gracell's dedication to tackling diverse cancer types through innovative therapies and state-of-the-art biotechnology.
